MB-207 / Fortress - LARVOL DELTA

Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID) (clinicaltrials.gov) - P1/2 | N=40 | Recruiting | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Trial completion date: Dec 2024 ➔ Dec 2032 | Trial primary completion date: Dec 2024 ➔ Dec 2032

Trial completion date • Trial primary completion date • Gene Therapies • Genetic Disorders • Immunology • Primary Immunodeficiency

Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID) (clinicaltrials.gov) - P1/2 | N=40 | Recruiting | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | N=30 ➔ 40

Enrollment change • Gene Therapies • Genetic Disorders • Immunology • Primary Immunodeficiency

Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID) (clinicaltrials.gov) - P1/2 | N=30 | Recruiting | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Suspended ➔ Recruiting | N=19 ➔ 30

Enrollment change • Enrollment open • Gene Therapies • Genetic Disorders • Immunology • Primary Immunodeficiency

Mustang Bio Announces Amendment and Closing of Strategic Manufacturing Partnership Transaction with uBriGene (Boston) Biosciences (GlobeNewswire) - "Mustang Bio, Inc...today announced that, on July 28, 2023, it amended its previously announced asset purchase agreement with uBriGene (Boston) Biosciences Inc....closed the transaction under the terms of the amended asset purchase agreement...Per the terms of the amended agreement, at closing, uBriGene acquired all of Mustang’s assets primarily relating to the manufacturing and production of cell and gene therapies for upfront consideration of $6 million in cash....At closing, Mustang and uBriGene also entered into a manufacturing services agreement, under which Mustang contracted uBriGene to manufacture Mustang’s lead product candidates. This includes the manufacturing of MB-106..."

Licensing / partnership • M&A • Brain Cancer • Chronic Lymphocytic Leukemia • CNS Tumor • Glioblastoma • Glioma • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Solid Tumor